Bevacizumab (Avastin) prior authorization at Cigna
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Cigna requires prior-authorization documentation for Bevacizumab (Avastin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Cigna reviews Bevacizumab (Avastin) prior authorizations against its medical policy . Cigna-specific context: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Cigna's medical policy URL referenced in the cover letter
Cigna's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Bevacizumab (Avastin)-specific denial patterns and context
Across payers (not just Cigna), Bevacizumab (Avastin)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Off-label use (ovarian, cervical maintenance)
- Plan-mandated biosimilar switch
- Site-of-care reduction
- Compounded intravitreal use denial (Avastin off-label for AMD)
Brand: Avastin. VEGF inhibitor. Biosimilars: Mvasi, Zirabev, Alymsys, Vegzelma, Avzivi. Off-label intravitreal use for wet AMD is widespread but commonly denied — appeals lean on AAO clinical practice and CATT trial.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Cigna denial sticks and the patient needs bridge access while appealing.
How Cigna approaches Biosimilars PAs
Cigna's Biosimilars reviewer typically anchors Bevacizumab prior-auth decisions on step therapy and specialty drug prior auth. Pharmacy-benefit review for Bevacizumab at Cigna is routed through Express Scripts (in-house since the 2018 acquisition). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Cigna treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Cigna is domiciled in CT, so unresolved appeals escalate to the CT insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Sold its Medicaid Advantage book to HCSC in 2023.
If the PA is denied
Cigna gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://cignaforhcp.cigna.com) with the same packet plus a peer-reviewed citation supporting Bevacizumab (Avastin)for the patient's indication.
Contact Cigna
- Provider portal: https://cignaforhcp.cigna.com
Frequently asked questions
What documentation does Cigna need for Bevacizumab (Avastin) prior auth?
Cigna's typical PA packet for Bevacizumab (Avastin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Cigna?
Standard Bevacizumab (Avastin) PA decisions at Cigna: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Cigna most often reject Bevacizumab (Avastin) for?
Across Cigna's book the common rejection patterns include: Mental health parity violations; Step therapy; Specialty drug prior auth. For Bevacizumab (Avastin) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Can Cigna force a mid-treatment switch from the reference biologic to Bevacizumab?
Cigna can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through Express Scripts (in-house since the 2018 acquisition). External-review escalation for Cigna fully-insured policies sits with the CT insurance department.
How do I prep for a peer-to-peer with Cigna on Bevacizumab (Avastin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Bevacizumab (Avastin) PA packet
Open ApprovalHelp — generate a Bevacizumab (Avastin) prior-auth packet tailored to Cigna's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com